Post on 10-Jul-2020
transcript
Engineering the Medicines of TomorrowCompany Update
November 2018
2
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including its financial guidance for 2018,
the commencement, timing and results of clinical trials and release of clinical data both in respect of its proprietary product candidates and of product
candidates of its collaborators, the development of commercial capabilities, in particular with respect to MOR208, and the transition of MorphoSys to a
fully integrated biopharmaceutical company, the expected time of launch of MOR208, interaction with regulators, including the potential approval of
MorphoSys’s current or future drug candidates, including discussions with the FDA regarding the potential approval to market MOR208, and expected
royalty and milestone payments in connection with MorphoSys’s collaborations. The forward-looking statements contained herein represent the judgment
of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial
condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results,
financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys’s
results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that
MorphoSys’s expectations regarding its 2018 results of operations may be incorrect, MorphoSys’s expectations regarding its development programs may be
incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval
requirements (including that MorphoSys may fail to obtain regulatory approval for MOR208 and that data from MorphoSys’s ongoing clinical research
programs may not support registration or further development of its product candidates due to safety, efficacy or other reasons), MorphoSys’s reliance on
collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in
MorphoSys’s Registration Statement on Form F-1 and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader
is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication
of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in
its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently
approved by the U.S. Food and Drug Administration (FDA), European Medicine Agency (EMA) or any other regulatory authority (except for
guselkumab/Tremfya®).
This presentation includes forward-looking statements.
© MorphoSys AG, November 2018
3© MorphoSys AG, November 2018
Investment Highlights
Proprietary Technology Platforms
Based on leading antibody platforms: over 100 active programs**
MOR208
Our lead product candidate, granted BTD in r/r DLBCL by the FDA; also in evaluation for
development in additional hematological malignancies; worldwide rights retained
Other Proprietary Programs
Multiple additional differentiated proprietary product candidates in development
For MOR106, we have recently signed an exclusive agreement with Novartis
MorphoSys US Inc.
Newly founded MorphoSys US Inc. to build own commercial capabilities
Broad Clinical Pipeline
29* product candidates across proprietary and partnered development programs
Tremfya®
First approved product; growing royalty participation; recent start of clinical development in
Crohn’s disease
* Includes Tremfya® which we still consider a phase 3 compound due to ongoing phase 3 studies in various indications
** Probability of success cannot be predicted
4
Building a Commercial, Product-Based Biopharmaceutical Company
© MorphoSys AG, November 2018
Business Model
PARTNERED DISCOVERY
Maximize utilization of the technology
collaborating close with pharma partners
Lucrative source of revenue from license fees,
milestone payments and royalties
PROPRIETARY DEVELOPMENT
Proprietary development, focus on oncology
Selective co-development programs
Retained rights translate into higher revenue
potential
Commercialize in selected settings
TECHNOLOGY: Antibodies (HuCAL & Ylanthia), Peptides; DISCOVERY PARTNERSHIPS (Novel Targets)
5
29 Product Candidates in Clinical Development, One Product Launched
© MorphoSys AG, November 2018
Our Clinical Pipeline
* We still consider Tremfya® a phase 3 compound due to ongoing studies in various indications
** MOR103/GSK3196165 is fully out-licensed to GSK
*** License agreement as of July 19, 2018
**** For development in China, Hong Kong, Taiwan, Macao
***** A phase 1 study in healthy volunteers was completed; MOR107 is currently in preclinical investigation with a focus on oncology indications
Program Partner Target Disease area Phase 1 Phase 2 Phase 3 Launched
Tremfya® (Guselkumab)* Janssen IL-23p19 Psoriasis
Gantenerumab Roche Amyloid-ß Alzheimer’s disease
MOR208 - CD19 Hematological malignancies
Anetumab Ravtansine (BAY94-9343) Bayer Mesothelin (ADC) Solid tumors
BAY1093884 Bayer TFPI Hemophilia
BHQ880 Novartis DKK-1 Multiple myeloma
Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal diseases
CNTO6785 Janssen - Inflammation
Ianalumab (VAY736) Novartis BAFF-R Inflammation
MOR103/GSK3196165** GSK GM-CSF Inflammation
MOR106*** Novartis/Galapagos IL-17C Inflammation
MOR202 I-Mab Biopharma**** CD38 Multiple myeloma
NOV-12 (MAA868) Novartis Factor XI Prevention of thrombosis
Setrusumab (BPS804) Mereo/Novartis Sclerostin Brittle bone syndrome
Tesidolumab (LFG316) Novartis C5 Eye diseases
Utomilumab (PF-05082566) Pfizer 4-1BB Cancer
Xentuzumab (BI-836845) BI IGF-1 Solid tumors
BAY2287411 Bayer Mesothelin Cancer
Elgemtumab (LJM716) Novartis HER3 Cancer
MOR107 (LP2-3)***** - AT2-R Not disclosed
NOV–7 (CLG561) Novartis - Eye diseases
NOV–8 Novartis - Inflammation
NOV-9 (LKA651) Novartis - Diabetic eye diseases
NOV-10 (PCA062) Novartis - Cancer
NOV-11 Novartis - Blood disorders
NOV-13 (HKT288) Novartis - Cancer
NOV-14 Novartis - Asthma
PRV-300 (CNTO3157) ProventionBio TLR-3 Inflammation
Vantictumab (OMP-18R5) OncoMed Fzd 7 Solid tumors
2
12
14
Partnered Discovery Programs
Proprietary Development Programs
Out-licensed Proprietary Developments Programs
6
Proprietary
Development Programs
© MorphoSys AG, November 2018
7
* For development in China, Hong Kong, Taiwan, Macao
** License agreement as of July 19, 2018
*** MOR103/GSK3196165 is fully out-licensed to GSK
**** A phase 1 study in healthy volunteers was completed; MOR107 is currently in preclinical investigation with a focus on oncology indications
Five Clinical Candidates
© MorphoSys AG, November 2018
Portfolio of Proprietary Development Segment
Program Partner Target Disease area Phase 1 Phase 2 Phase 3
MOR208 - CD19
DLBCL (B-MIND)
DLBCL (L-MIND)
CLL (COSMOS)
MOR202I-Mab
Biopharma*CD38 Multiple myeloma
MOR106**Novartis/
GalapagosIL-17C
Atopic dermatitis (iv)
Atopic dermatitis
(bridging study) (sc)
MOR103/GSK3196165*** GSK GM-CSF Inflammation
MOR107**** - AT2-ROncology under
investigation
6 proprietary or co-developed programs in discovery and 1 in preclinical phase
Proprietary Development Programs
Out-licensed Proprietary Developments Programs
8
W. Jurczak et al.; ASH 2016
An Investigational Anti-CD19 Product Candidate for B Cell Malignancies
The Product Candidate
IgG1 antibody targeting CD19
Fc-engineered to enhance target cell-killing
Suggested Modes of Action
ADCC, phagocytosis and direct cytotoxicity
Promising Preclinical and Clinical Package
Depletes B cells in in vitro and in vivo models
Preclinical data supports multiple combination
therapies
Exploring potential biomarker for patient-
specific treatment
© MorphoSys AG, November 2018
MOR208: Proprietary Antibody in Hematological Cancers
ADCC: Antibody-Dependent Cell-Mediated Cytotoxicity
ADCP: Antibody-Dependent Cell-Mediated Phagocytosis
9
* GLOBOCAN report 2012; ** Raut et al., 2014; *** Maurer et al., 2014; **** Market Research AplusA
High Unmet Medical Need
© MorphoSys AG, November 2018
MOR208: Diffuse Large B Cell Lymphoma
Very Aggressive and Resistant Tumor
Up to 40% of all patients with DLBCL either fail
to respond to or show relapse on initial
therapy***
Relapsed or Refractory DLBCL
Disease is difficult to treat
Prognosis is poor, especially for elderly and frail
patients
Current treatment options are limited
High unmet medical need
Potential opportunity in r/r DLBCL 2nd+****
U.S.: ca. 8,500 patients non-eligible for HDCT
and ASCT
Most frequently-occurring malignant
lymphoma worldwide
40%
r/r
DLBCL***
33% of NHL
cases are
DLBCL**
Non-Hodgkin Lymphoma
approx. 386,000 cases*
10
* Data cut-off June 5, 2018; 81 patients enrolled; data from abstract accepted for oral presentation at ASH 2018, published Nov. 1, 2018
© MorphoSys AG, November 2018
L-MIND: Updated Preliminary Results*
Preliminary Results
Complete response: 33% (n=27)
Partial response: 25% (n=20)
Stable disease: 15% (n=12)
Median PFS: 16.2 months (95% confidence interval: 6.3-NR)
12 month PFS: 70%
Median duration of response: not reached (95% confidence interval: NR-NR)
Median overall survival: not reached (95% confidence interval: 18.6-NR)
12 month OS: 73%
Treatment-emergent Adverse Events (TEAE)
Any grade/grade ≥3: neutropenia in 39/35 (48%/43%) patients, thrombocytopenia 26/14 (32%/17%),
anemia 25/7 (31%/9%), diarrhea 24/1 (30%/1%), pyrexia 18/1 (22%/1%), asthenia 16/2 (20%/2%)
Patient Baseline Characteristics
Median age: 72 years
Median prior lines of therapy: 2
Median follow-up: 12 months
Overall response rate: 58%
11
Please Note Limitations of Cross-trial Comparisons to Literature Data
© MorphoSys AG, November 2018
MOR208: L-MIND vs. Lenalidomide Regimens in r/r DLBCL
Parameter L-MIND
Cut-off
June 5th, 2018
Witzig et al.,
2011
Czuzcman et al.,
2017
Wang et al.,
2013
Morschhauser et
al.,
ASH 2016
Compound(s) MOR208 + LEN LEN Monotherapy LEN Monotherapy RTX + LEN OBI + LEN
Phase 2 2 2/3 2 2
Evaluable patient
population
n=81 n=108 n=51 n=32 n=71
Objective
response rate
58% 28% 28% 28% 45%
Complete
response rate
33% 7% 10% 22% 16%
Median PFS,
months
16.2 2.7 3.1 2.8 4.1
MOR208 is an investigational drug that is not approved by FDA for any use.
No head-to-head clinical studies have been performed between MOR208 and the other products in this table. As such,
these cross-trial comparisons of literature data have significant limitations.
The data in this table have been prepared at the request of, and for the sole benefit of, the investor community.
12
* For all patients
Please Note Limitations of Cross-trial Comparisons to Literature Data
© MorphoSys AG, November 2018
MOR208: Existing and Upcoming Approaches in r/r DLBCL
Parameter L-MIND
Cut-off
June 5, 2018
Dang et al.,
2014
Sehn et al.,
2018
Scholar-1
Crump et al.,
2017
Juliet
Schuster et al.,
2018
Zuma-1 Neelapu
et al., 2017
Compound(s) MOR208 + lenalidomide
RTX + bendamustine
Polatuzumab + RTX +
bendamustine
Salvage chemotherapies
+ radiation
Tisagenlecleucel(CD19 CAR-T)
Axi-CEL(CD19 CAR-T)
Phase 2 3 2 Retrospectivestudy
2 2
Evaluable patient population
r/r DLBCLn=81
r/r DLBCLn=137
r/r DLBCLn=40
r/r DLBCLn=636
r/r DLBCLn=115
r/r NHLn=101
(DLBCL n=77)
Objective response rate
58% 49% 70% 26% 54%/37%Best/@6 mo.
82%/48%Best/@6 mo.
Complete response rate
33% 18% 58% 7% 40%/30%Best/@6 mo.
58%/46%Best/@6 mo.
Median PFS, months
16.2 4.2 7.6 n/a n/a 5.8*
MOR208 is an investigational drug that is not approved by FDA for any use.
No head-to-head clinical studies have been performed between MOR208 and the other products in this table. As such,
these cross-trial comparisons of literature data have significant limitations.
The data in this table have been prepared at the request of, and for the sole benefit of, the investor community.
13
More information about ongoing trials at clinicaltrials.gov
Opportunity Across a Spectrum of B Cell Malignancies
© MorphoSys AG, November 2018
MOR208: Development Plan
Indication Trial / Phase Design Timeline
r/r DLBCL L-MIND
Phase 2
Lenalidomide + MOR208 in relapsed or
refractory DLBCL patients ineligible for
HDCT and ASCT
Data of 81 patients to
be presented at ASH,
final data expected
mid 2019
B-MIND
Phase 2/3
Bendamustine + MOR208 vs. bendamustine +
rituximab in relapsed or refractory DLBCL
patients ineligible for HDCT and ASCT
Primary analysis
expected in Q4 2019
r/r CLL COSMOS
Phase 2
Cohort A: MOR208 + idelalisib
Cohort B: MOR208 + venetoclax
Patients with r/r disease while on a BTK
inhibitor or who are intolerant to such
treatment
Updates at medical
conferences 2018
(EHA, 2018: cohort A;
ASH 2018: cohort B)
DLBCL Front line Under evaluation
Indolent
lymphomas
Under evaluation
14
Partnered for Greater China; Being Evaluated for Indications Beyond MM
The Product Candidate
ADCC & ADCP cell-killing mechanisms
Results of phase 1/2a trial in MM to be presented
at ASH 2018
MOR is evaluating future development in
indications other than MM, among those
autoimmune disorders
Partnering Deal with I-Mab in MM (Nov. 2017)
I-Mab received exclusive development and
commercialization rights in China, Taiwan,
Hong Kong and Macau
Payments to MorphoSys
USD 20m upfront
Up to USD 100m milestones
Tiered, double digit royalties
I-Mab will commence a pivotal study of MOR202
in MM in Q1 2019
© MorphoSys AG, November 2018
MOR202: A HuCAL Antibody Directed Against CD38
ADCC: Antibody-Dependent Cell-Mediated Cytotoxicity
ADCP: Antibody-Dependent Cell-Mediated Phagocytosis
ADCC
ADCP
15
Partnering Deal with Novartis
*According to CT.gov
MOR106: Development in Atopic Dermatitis
© MorphoSys AG, November 2018
The Product Candidate
Ylanthia antibody targeting IL-17C, a cytokine implicated in a number of inflammatory skin disorders
Originates from 50/50 co-development with Galapagos
Phase 2 trial “IGUANA” in 180 patients with moderate to severe atopic dermatitis
Study started in May 2018, estimated primary completion September 2019*
Phase 1 bridging study with subcutaneous formulation
Study started in September 2018, estimated primary completion August 2019*
Worldwide, exclusive partnering deal with Novartis signed July 19, 2018
MorphoSys / Galapagos remain engaged and responsible for additional studies in atopic dermatitis
Novartis will sponsor clinical PoC studies in other indications
Up-front payment of EUR 95 million
Front-loaded milestone package of up to approximately EUR 850 million
Tiered double-digit royalties (low teens to low twenties) on net commercial sales
MorphoSys and Galapagos to share all payments from Novartis equally
Novartis to fund all future research, development, manufacturing and commercialization costs
16
* According to GSK’s Q3 press release, October 2018; **According to GSK during the JP Morgan Biotech CEO Call, September 2018
An Anti-GM-CSF Antibody for Inflammatory Diseases
© MorphoSys AG, November 2018
MOR103/GSK3196165
The Product Candidate
HuCAL antibody fully out-licensed to GSK in 2013
EUR 22.5m upfront payment
Milestone potential of up to EUR 423m
Tiered, double-digit royalties on net sales
GSK solely responsible for the development
and commercialization of the compound
On 22 October, data from the phase II study
(BAROQUE) of GSK3196165 in patients with
rheumatoid arthritis were presented at ACR.*
GSK mentioned rapid onset and marked benefit
on clinically meaningful endpoints such as pain
that support further clinical development for
RA.*
Further development plans: GSK to “be talking
hopefully to regulators before moving into
Phase 3.”**
Suggested mode of action:
17
Proprietray Program for Development in Oncology
Role of C5a/C5aR in the Tumor Environment
Attraction of myeloid-derived suppressor cells
thereby dampening anti-tumor responses
Blocking the interaction intends to release this
blockade of anti-tumor responses
Strategic Partnering Agreement with I-Mab as of
Nov 15th, 2018
I-Mab received exclusive rights to develop and
commercialize MOR210 in China, Hong Kong,
Macau, Taiwan and South Korea, while MorphoSys
will retain rights in the rest of the world
USD 3.5m upfront payment
Up to USD 101.5m milestones
Tiered, mid-single-digit royalties
I-Mab to receive low-single-digit royalties on net
sales outside its territories and a tiered
percentage of sub-licensing revenue
© MorphoSys AG, November 2018
MOR210: Preclinical Candidate Targeting C5aR
18
* For development in China, Hong Kong, Taiwan, Macao
** License agreement as of July 19, 2018
*** MOR103/GSK3196165 is fully out-licensed to GSK
Proprietary Portfolio: Upcoming Newsflow 2018
Compound Indication Expected Newsflow
MOR208 DLBCL
L-MIND: Continue analysis of maturing data from the
study – Update at ASH 2018
Updates on further development plans in front-line
DLBCL and indolent lymphomas
CLL
COSMOS: Updates at medical conferences 2018
Cohort A: EHA June 16, 2018
Cohort B: ASH 2018
MOR202
(I-Mab Biopharma*)Multiple myeloma Results phase 1/2a study – ASH 2018
MOR106** Atopic dermatitisStart of phase 2 trial – Q2 2018
Start of phase 1 bridging study – Sept. 2018
MOR103/
GSK3196165***Rheumatoid arthritis
Data from phase 2a and 2b trial in RA and phase 2a in
OA presented at ACR
© MorphoSys AG, November 2018
19
Partnered Discovery
Programs
© MorphoSys AG, November 2018
20
* We still consider Tremfya® a phase 3 compound due to ongoing studies in various indications
24 Product Candidates in Clinical Development, Thereof One Launched
© MorphoSys AG, November 2018
Partnered Discovery Programs Clinical Pipeline
Program Partner Target Disease area Phase 1 Phase 2 Phase 3 Launched
Tremfya® (Guselkumab)* Janssen IL-23p19 Psoriasis
Gantenerumab Roche Amyloid-ß Alzheimer’s disease
Anetumab Ravtansine (BAY94-9343) Bayer Mesothelin (ADC) Solid tumors
BAY1093884 Bayer TFPI Hemophilia
BHQ880 Novartis DKK-1 Multiple myeloma
Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal diseases
CNTO6785 Janssen - Inflammation
Ianalumab (VAY736) Novartis BAFF-R Inflammation
NOV-12 (MAA868) Novartis Factor XI Prevention of thrombosis
Setrusumab (BPS804) Mereo/Novartis Sclerostin Brittle bone syndrome
Tesidolumab (LFG316) Novartis C5 Eye diseases
Utomilumab (PF-05082566) Pfizer 4-1BB Cancer
Xentuzumab (BI-836845) BI IGF-1 Solid tumors
BAY2287411 Bayer Mesothelin Cancer
Elgemtumab (LJM716) Novartis HER3 Cancer
NOV–7 (CLG561) Novartis - Eye diseases
NOV–8 Novartis - Inflammation
NOV-9 (LKA651) Novartis - Diabetic eye diseases
NOV-10 (PCA062) Novartis - Cancer
NOV-11 Novartis - Blood disorders
NOV-13 (HKT288) Novartis - Cancer
NOV-14 Novartis - Asthma
PRV-300 (CNTO3157) ProventionBio TLR-3 Inflammation
Vantictumab (OMP-18R5) OncoMed Fzd 7 Solid tumors
11
11
In addition, 55 partnered programs are in discovery, 24 in preclinic
21
* According to Janssen‘s quarterly reports
Humira® is a trademark of AbbVie Biotechnology Ltd.; Cosentyx® is a trademark of Novartis AG
Janssen’s Novel Biologic Being Developed for Immune-Mediated Diseases
The Drug
First-in-class anti-IL-23 human monoclonal antibody
Generated using MorphoSys’s HuCAL technology
Status
Approved in U.S., EU, Canada and other countries for moderate-to-severe plaque psoriasis and in Japan for psoriasis, psoriatic arthritis and palmoplantar pustulosis
Tremfya® sales Q3 vs. Q2 rose by 36%*; royalty income for 2018 expected in range EUR 12-17m at constant USD currency
Differentiation
Superior clinical efficacy compared to Humira®
Convenience: 8-weekly sc dosing
Ongoing Clinical Development Phase 3 Trials
Phase 3 head-to-head vs. Cosentyx® in plaque psoriasis: Results expected in early 2019
Psoriatic arthritis: 2 phase 3 trials ongoing
Crohn’s disease: Phase 2/3 program started in July 2018
Hidradenitis Suppurativa: Phase 2 start announced in Nov 2018
Partnered Discovery Program: Tremfya® (Guselkumab)
© MorphoSys AG, November 2018
22
Differentiated Drugs for Treatment of Patients Suffering Serious Diseases
Technology Platform
HuCAL
Original, ground-breaking platform
First product launched
25 clinical, various pre-clinical &
discovery programs
Lanthipeptides
High target molecule selectivity and
high in vivo stability
Agonistic or antagonistic activity
possible
Bi-specifics
Proprietary formats
Enhanced tumor cell killing via co-
stimulation of tumor-specific effector
T cells
Ylanthia
Latest antibody library, one of the
largest in the industry
Covers huge epitope space, designed for
difficult targets (e.g. MHC/peptide
complexes; GPCRs)
Built to deliver superior antibodies
First program in clinic
Proprietary Human Antibody Libraries
© MorphoSys AG, November 2018
23
* According to clinicaltrials.gov as of November 11, 2018; anticipated primary completion dates through 2019, actual events could differ
Cosentyx® is a trademark of Novartis AG
Clinical Phase 2 and 3 Read-outs Potentially Due until end of 2019*
© MorphoSys AG, November 2018
Partnered Pipeline: Expected Primary Completion Dates
Phase 2 Phase 3
Anetumab Ravtansine (BAY94-9343;
Mesothelin)
Cancer
Bimagrumab (BYM338; ActRIIB)
Sarcopenia (dose ranging study)
Gantenerumab (Amyloid-ß)
Mild Alzheimer’s disease
(open label extension)
Bimagrumab (BYM338; ActRIIB)
Sarcopenia (off drug extension)
Bimagrumab (BYM338; ActRIIB)
Diabetes Mellitus (Type 2)
Guselkumab (IL-23p19)
Moderate to severe plaque psoriasis
(ECLIPSE; Head-to-head with Cosentyx®)
Bimagrumab (BYM338; ActRIIB)
Muscular atrophy after hip fracture surgery
Ianalumab (VAY736; BAFF-R)
Primary Sjögren’s syndrome
Guselkumab (IL-23p19)
Moderate to severe plaque psoriasis
(POLARIS)
Ianalumab (VAY736; BAFF-R)
Pemphigus Vulgaris
Setrusumab (BSP804; Sclerostin)
Osteogenesis Imperfecta (Type I, III, IV)
Guselkumab (IL-23p19)
Moderate to severe plaque psoriasis
Utomilumab (PF-05082566; 4-1BB)
Cancer
Xentuzumab (BI-836845; IGF-1)
Prostate cancer (+ enzalutamide)
Guselkumab (IL-23p19)
Pustular or Erythrodermic Psoriasis
Xentuzumab (BI-836845; IGF-1)
Breast cancer
Guselkumab (IL-23p19)
Psoriatic arthritis
(Discover-1)
24
* Guidance update on July 19, 2018 following MOR106 Deal with Novartis; effective on September 10, 2018 after U.S. antitrust clearance.
** Revenues are expected to include royalty income from Tremfya® ranging from EUR 12-17 million on constant USD currency.
© MorphoSys AG, November 2018
Financial Guidance 2018
Total ordinary shares issued (as of October 31, 2018): 31,839,572
In EUR million Reported FY2017 Q1-Q3 2018 Guidance FY2018*
66.8 66.0 67 to 72**
99.1 55.1 87 to 97
(67.6) (13.0) (55) to (65)
Group Revenues
Proprietary R&D Expenses (incl. Technology Development)
EBIT
Cash Position End of Q3 2018: EUR 481.2 m
25
To Become A Fully-Integrated Biopharmaceutical Company
© MorphoSys AG, November 2018
Our Strategy
Explore options for the future development of MOR202 in
indications other than MM
Build our commercial capabilities in connection with the
potential future approval of MOR208
Realize the value of our technology platforms by using them
to discover and develop additional proprietary programs
Continue to advance the development of our lead product
candidate MOR208 towards regulatory approval
26
Appendix
© MorphoSys AG, November 2018
27
Ongoing Clinical Trials (1)
© MorphoSys AG, November 2018
Clinical Programs
Program Partner Target Indication Phase 1 Phase 2 Phase 3 Launched
Guselkumab Janssen/J&J IL23p19 Plaque psoriasis
(CNTO1959) Plaque psoriasis (VOYAGE 1)
Plaque psoriasis (VOYAGE 2)
Pustular/erythrodermic psoriasis
Plaque psoriasis
Plaque psoriasis (POLARIS)
Palmoplantar pustulosis
Moderate to severe plaque psoriasis (SelfDoseTM device)
Moderate to severe plaque psoriasis (ECLIPSE)
Psoriatic arthritis (PsA) (Discover-1)
Psoriatic arthritis (PsA)
Chronic plaque psoriasis (pediatric participants) (PROTOSTAR)
Crohn’s Disease (GALAXI 1)
Hidradenitis suppurativa (HS)
Gantenerumab Roche Amyloid-ß Early Alzheimer՚s disease (GRADUATE-1)
Early Alzheimer՚s disease (GRADUATE-2)
Mild Alzheimer’s disease (Marguerite RoAD) (OLE)
Prodromal Alzheimer’s disease (Scarlett RoAD) (OLE)
Genetically predisposed for Alzheimer’s disease (DIAN)
MOR208 - CD19 Diffuse large B cell lymphoma (DLBCL) (B-MIND)
Chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) (COSMOS)
Diffuse large B cell lymphoma (DLBCL) (L-MIND)
Anetumab Ravtansine Bayer Mesothelin Mesothelioma (MPM)
(BAY94-9343) Cancer multi-indications
BAY1093884 Bayer TFPI Hemophilia A or B
Hemophilia
BHQ880 Novartis DKK-1 Multiple myeloma (MM) (renal insufficiency)
Smoldering multiple myeloma
Bimagrumab Novartis ActRIIB Hip fracture surgery (efficacy, safety)
(BYM338) Sarcopenia (dose-ranging)
Sarcopenia (withdrawal extension study)
Type 2 diabetes
CNTO6785 Janssen/J&J Chronic obstructive pulmonary disease (COPD)
Rheumatoid arthritis (RA)
Partnered Discovery Programs
Proprietary Development Programs
28
* MOR103/GSK3196165 is fully out-licensed to GSK
** License agreement as of July 19, 2018
*** For development in China, Hong Kong, Taiwan, Macao
Ongoing Clinical Trials (2)
© MorphoSys AG, November 2018
Clinical Programs
Program Partner Target Indication Phase 1 Phase 2 Phase 3 Launched
Ianalumab (VAY736) Novartis BAFF-R ADCC mediated B cell depletion and BAFF-R blockade (AMBER)
Pemphigus vulgaris
Idiopathic pulmonary fibrosis
Rheumatoid arthritis (RA)
Primary Sjögren's syndrome (efficacy & safety)
Chronic lymphocytic leukemia (combo with ibrutinib)
MOR103/GSK3196165* GSK GM-CSF Rheumatoid arthritis (RA)
MOR106** Novartis/Galapagos IL-17C Atopic dermatitis (IGUANA) (iv)
Atopic dermatitis (bridging study) (sc)
MOR202 I-Mab*** CD38 Multiple myeloma (MM)
NOV-12 (MAA868) Novartis Factor XI Prevention of thrombosis
Atrial fibrillation
Setrusumab (BPS804) Mereo/Novartis Sclerostin Brittle bone disease (OI) (Type I, III, IV) (ASTEROID)
Tesidolumab (LFG316) Novartis C5 Paroxysmal nocturnal hemoglobinuria
Utomilumab Pfizer 4-1BB Breast cancer (AVIATOR)
(PF-05082566) Acute myeloid leukemia (AML)
Solid tumors (combo with ISA101b vaccination)
Advanced malignancies (combo with avelumab & PF-04518600)
Solid tumors (combo with PF04518600)
Colorectal cancer (combo with cetuximab & irinotecan)
Advanced ovarian cancer (T cell immunotherapy)
R/R DLBCL & MCL (avelumab plus utomilumab-based combination therapy)
Breast cancer (combo with trastuzumab emtansine or trastuzumab)
Follicular lymphoma (combo with rituximab)
Xentuzumab BI IGF-1 Breast cancer
(BI-836845)Castration-resistant prostate cancer (CRPC) (combo with
enzalutamide)
Solid tumors (Japan)
Solid tumors (combo with abemaciclib)
EGFR mutant non-small cell lung cancer (NSCLC)
Partnered Discovery Programs
Proprietary Development Programs
Out-licensed Proprietary Developments Programs
29
* A phase 1 study in healthy volunteers was completed. MOR107 is currently in preclinical investigation with a focus on oncology indications
Ongoing Clinical Trials (3)
© MorphoSys AG, November 2018
Clinical Programs
Program Partner Target Indication Phase 1 Phase 2 Phase 3 Launched
BAY2287411 Bayer Mesothelin Cancer
Elgemtumab (LJM716) Novartis HER3 HER2+ cancer (combo with BYL719 & trastuzumab)
MOR107 (LP2-3)* - AT2-R Not disclosed
NOV-7 (CLG561) Novartis n.d. Eye diseases
NOV-8 Novartis n.d. Inflammation
NOV-9 (LKA651) Novartis n.d. Diabetic eye diseases
NOV-10 (PCA062) Novartis n.d. Cancer
NOV-11 Novartis n.d. Blood disorders
NOV-13 (HKT288) Novartis n.d. Cancer
NOV-14 Novartis n.d. Asthma
PRV-300 (CNTO3157) ProventionBio TLR-3 Colitis (PULSE)
Vantictumab Oncomed Fzd 7 Breast cancer (combo with paclitaxel)
(OMP-18R5) Pancreatic cancer (combo with nap-paclitaxel &
gemcitabine)
Partnered Discovery Programs
Proprietary Development Programs
30
Please see our website www.morphosys.com for more information about MorphoSys shares and ADSs
Dual Listing
MorphoSys AG Stock Information
© MorphoSys AG, November 2018
Listing in Germany on the
Frankfurt Stock Exchange
Security paper Ordinary shares
(ORD)
Symbol MOR
ISIN DE0006632003
Security Code Number 5531000
Currency EUR
1st trading day March 9, 1999
Listing in the U.S. on the
Nasdaq Global Market
Security paper American depository
shares (ADS)
Symbol MOR
CUSIP 617760202
ISIN US6177602025
Currency US-$
1st trading day April 19, 2018
Ratio 4 ADSs : 1 ORD
Depository Bank BNY Mellon
31© MorphoSys AG, November 2018
Covering Analysts
Institution Contact
Berenberg Alistair Campbell
Bloomberg Intelligence Cinney Zhang
Bryan Garnier Gary Waanders
Commerzbank Daniel Wendorff
Deutsche Bank Gunnar Romer
Goldman Sachs Keyur Parekh
HSBC Steve McGarry
Independent Research GmbH NN
J.P. Morgan Cazenove James Gordon
JMP Konstantinos N. Aprilakis
Kempen & Co. Anastasia Karpova
Landesbank Baden-Württemberg Timo Kürschner
Oddo BHF Igor Kim
Piper Jaffray Danielle Brill
Royal Bank of Canada Zoe Karamanoli
MOR208, MOR202, MOR106, MOR103, anetumab ravtansine, gantenerumab and all other product candidates mentioned here are investigational drugs and have not been
approved by the FDA or other ex-US regulatory agencies. HuCAL® , HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high
potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group. Tremfya® is a trademark of Janssen Biotech, Inc.
www.morphosys.com
Thank You
Corporate Communications & IR
Phone +49 (0)89 / 899 27-404
Fax +49 (0)89 / 899 27-5404
Email investors@morphosys.com